OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether osteoprotegerin and RANKL (receptor
activator of nuclear factor-κB ligand) are involved in bone remodeling in patients with
primary hyperparathyroidism (PHPT), and whether alendronate may be useful in treatment of the
patients with PHPT who are not treated with parathyroidectomy.